Mochida SSRI Drug To Achieve ¥10 Billion Domestic Sales
This article was originally published in PharmAsia News
Executive Summary
Mochida Pharmaceutical President Mochida Naoyuki said the company's growth will hinge on its selective serotonin reinhibitor escitalogram, which is expected to be launched this year